In 2012, the Dutch multidisciplinary multicentre registry for PH (PulmoCor) was initiated by three tertiary PH centres and supported by the Interuniversity Cardiology Institute of the Netherlands (ICIN). Nowadays, six tertiary PH centres participate in this program (5 university medical centres and 1 non-university hospital). A working group including PH specialists (both cardiologists and pulmonologists) of all participating centres was established and regulations for this project have been drawn up. Several privacyenhancing technologies have been used in accordance with the Dutch Privacy protections laws for data collection.
The aims of the PulmoCor registry are to further optimise patient care and research in the field of PH, and the joint collaboration between the national and international PH centres. Interestingly, the same structured webbased PH database, specially developed for the management of PH patients (PAHtool, Inovolutus, Portugal), is used in other international PH centres as well, both European and non-European [4] . The PulmoCor registry will facilitate investigation of the epidemiology of specific subtypes of PH, the treatment and long-term outcome. It will increase the awareness of this rare disease throughout the Netherlands. Furthermore, the registry can be used as clinical database as well.
Based on the current international guidelines, all PH centres used a standardised diagnostic approach for PH analysis [1] . Different data regarding the initial work-up and followup could be included in the PulmoCor registry. Each participating PH centre is using the secured uniformly structured database for the registration of their patients and these data are only accessible by this centre. To date, a total of 1493 patients with pulmonary hypertension (both prevalent and incident cases) have been included in the PulmoCor registry. In Fig. 1 , this total group is shown according to the . Group 1 Pulmonary arterial hypertension; Group 2 PH due to left heart disease; Group 3 PH due to lung disease and/or hypoxia; Group 4 Chronic thromboembolic PH and other pulmonary artery obstructions; Group 5 PH with unclear and/or multifactorial mechanisms [1] . (CTD connective tissue disease, HIV human immunodeficiency virus, CHD congenital heart disease, PVOD pulmonary veno-occlusive disease, PCH pulmonary capillary haemangiomatosis) clinical classification (a) and the subgroup of patients with pulmonary arterial hypertension (PAH), group 1 (b).
The uniformly designed PulmoCor registry data acquisition will increase the value of national collaboration both clinically and scientifically.
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